COVID-19 vaccination in our transplant recipients: The time is now.

Journal Article (Editorial)

We are entering 2021 with an expanding and effective COVID-19 vaccine armamentarium. Recent interim results from COVID-19 vaccine trials, including more than 80,000 participants worldwide, demonstrate remarkable efficacy and low rate of serious adverse events. Based on experience with other vaccines in transplant recipients and knowing the risk of severe COVID-19 in this population, we believe that COVID-19 vaccines provide potential benefit with minimal risk. We strongly support and encourage COVID-19 vaccination of our transplant recipients.

Full Text

Duke Authors

Cited Authors

  • Aslam, S; Goldstein, DR; Vos, R; Gelman, AE; Kittleson, MM; Wolfe, C; Danziger-Isakov, L

Published Date

  • March 2021

Published In

Volume / Issue

  • 40 / 3

Start / End Page

  • 169 - 171

PubMed ID

  • 33487534

Pubmed Central ID

  • PMC7834006

Electronic International Standard Serial Number (EISSN)

  • 1557-3117

Digital Object Identifier (DOI)

  • 10.1016/j.healun.2020.12.009


  • eng

Conference Location

  • United States